Hormones and vasoprotection

Hypertension

Volumn 33, Issue 1 II, 1999, Pages 170-176

  Oparil, Suzanne ^a  

^a 1034 Zeigler Research Bldg   (United States)

Author keywords

Estrogen; Fibroblast; Gender; Hormones; Muscle, smooth; Progestin; Women

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; HORMONE; SEX HORMONE;

ANIMAL MODEL; ATHEROSCLEROSIS; CAROTID ARTERY DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FIBROBLAST; GENE THERAPY; HORMONE ACTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; ANIMAL; CARDIOVASCULAR DISEASE; DISEASE MODEL; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HORMONES; HUMANS; MALE; PROGESTINS; RATS;

EID: 0032926370     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.33.1.170     Document Type: Conference Paper

References (56)

1. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barren-Connor E. Cardiovascular disease in women: statement for healthcare professionals from the American Heart Association. Circulation. 1997; 96:2468-2482.
2. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol. 1996;87:S36-S43.
3. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
4. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154:1333-1339.
5. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335: 453-461.
6. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol. 1992;69:176-178.
7. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman EM, Faxon DP, Jacobs AK, Topol EJ, Califf RM. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 1996;28:1111-1118.
8. O'Keefe JH, Kim SC, Hall RR, Cochran VC, Lawthorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol. 1997;29:1-5.
9. Abu-Halawa SA, Thompson K, Kirkeeide RL, Vaughn WK, Rosales O, Fujisi K, Schroth G, Smalling R, Anderson HV. Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women. Am J Cardiol. 1998;82:409-413.
10. Di Mario C, Gil R, Camenzind E, Ozaki Y, von Birgelen C, Umans V, de Jaegere P, de Feyter PJ, Roelandt JR, Serruys PW. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol. 1995;75:772-777.
11. Barren-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA. 1989;261:2095-2100.
12. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than non-users? Am J Epidemiol. 1996;143:971-978.
13. Rossouw JE. Estrogens for prevention of coronary heart disease: putting the brakes on the bandwagon. Circulation. 1996;94:2982-2985.
14. Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and Estrogen/Progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998;19:314-335.
15. HulIey S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280: 605-613.
16. Petitti DB. Hormone replacement therapy and heart disease prevention. JAMA. 1998;280:650-652.
17. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998; 19:61-109.
18. PEPI Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;3:199-208.
19. Miller VM, Vanhoutte PM. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol. 1991; 261:R1022-R1027.
20. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 1994;24:1757-1761.
21. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation. 1995;91:1952-1958.
22. Miyagawa K, Rösch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997;3:324-327.
23. Williams JK, Adams MR. Estrogens, progestins and coronary artery reactivity. Nat Med. 1997;3:273-274.
24. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:217-221.
25. Lee W-S, Harder JA, Yoshizumi M, Lee M-E, Haber E. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med. 1997;3: 1005-1008.
26. Orimo A, Inoue S, Ouchi Y, Orimo H. Vascular smooth muscle cells possess estrogen receptors and respond to estrogen. Ann N Y Acad Sci. 1995;748:592-594.
27. Farhat MY, Abi-Younes S, Ramwell PW. Non-genomic effects of estrogen and the vessel wall. Biochem Pharmacol. 1996;51:571-576.
28. Foegh ML, Zhao Y, Farhat M, Ramwell PW. Oestradiol inhibition of vascular myointimal proliferation following immune, chemical and mechanical injury. Ciba Found Symp. 1995;191:139-145.
29. Geary RL, Adams MR, Benjamin ME, Williams JK. Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimai hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys. J Am Coll Cardiol. 1998;31:1158-1164.
30. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis: lack of effect of added progesterone. Arteriosclerosis. 1990;10:1051-1057.
31. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries in premenopausal women. Circulation. 1994;89:1501-1510.
32. Clowes AW, Collazzo RE, Karnovsky MJ. A morphologic and permeability study of luminal smooth muscle cells after arterial injury in the rat. Lab Invest. 1978;39:141-150.
33. Chen SJ, Chen YF, Miller DM, Li HB, Oparil S. Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo. Circulation. 1994;90:2468-2473.
34. Van Dyke MW, Dervan PB. Chromomycin, mithramycin and olivomycin binding sites on heterogeneous deoxyribonucleic acid: footprint with (methidiumpropyl-EDTA) iron (II). Biochemistry. 1983;22:2373-2377.
35. 2 promoters. Biochemistry. 1991; 30:4290-4297.
36. Holt JT, Radner RL, Nienhuis AW. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol. 1988:963-973.
37. Chen SJ, Li H, Durand J, Oparil S, Chen YF. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation. 1996;93:577-584.
38. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-medialed inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996;94:2221-2227.
39. Oparil S, Levine RL, Chen SJ, Durand J, Chen YF. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation. 1997;95:1301-1307.
40. Schwartz SM, DeBlois D, O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res. 1995;77:445-465.
41. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle cell growth in the absence of endothelium. Lab Invest. 1983;49:327-333.
42. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208-215.
43. Thompson JA, Li G, Chen Y-F, Oparil S. Estrogen inhibits migration of adventitial fibroblasts in vitro. In: Program and abstracts of the North American Vascular Biology Organization (NAVBO), April 15-18, 1998; San Francisco, Calif. Abstract 27.
44. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 1996;4:1655-1664.
45. Shi Y, Pieniek M, Fard A, O'Brien JE, Mannion JD, Zalewski A. Adventitial remodeling following coronary arterial injury. Circulation. 1996;3:340-348.
46. Shi Y, O'Brien JE, Ala-Kokko L, Chung W, Mannion JD, Zalewski A. Ongin of extracellular matrix synthesis during coronary repair. Circulation. 1997;95:997-1006.
47. Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P, Dodge GR, Hall DJ, Shaheen F, Zalewski A. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 1994;90:944-951.
48. Simmons M, Edelman ER, Rosenberg RD. Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J Clin Invest. 1994;93:2351-2356.
49. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimai hyperplasia after vascular injury in inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458-1464.
50. Biro S, Fu YM, Yu Zx, Epstein SE. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration Proc Natl Acad Sci U S A. 1993;90: 654-658.
51. Saphir O, Gore I. Evidence for an inflammatory basis of coronary arteriosclerosis in the young. Arch Pathol. 1950;49:418-426.
52. Kohchi K, Takebayashi S, Hiroki T, Nobuyoshi M. Significance of adventitial inflammation of the coronary artery in patients with unstable angina: results at autopsy. Circulation. 1985;71:709-716.
53. Prescott MF, McBride CK, Court M. Development of intimai lesions after leukocyte migration into the vascular wall. Am J Pathol. 1989;135: 835-846.
54. Beesley JE, Honey AC, Martin JF. Ultrastructural assessment of lesion development in the collared rabbit carotid artery model. Cells and Materials. 1992;2:201-208.
55. Li G, Chen YF, Oparil S, Thompson JA. Estrogen indirectly inhibits adventitial fibroblast migration. Circulation. 1998 (AHA abstract-accepted for publication). In press.
56. Li G, Chen S-J, Chen Y-F, Durand J, Thompson JA, Oparil S. Adventitial fibroblasts contribute to neointima formation in balloon injured rat carotid arteries. Circulation 1998;98(suppl I):I-182. Abstract 940.